TICKERNERD
Menu
RLAYRLAYHealthcare · Biotechnology

RLAY Stock Forecast: Relay Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$19
−0.11% on the day

The 14 Wall Street analysts covering Relay Therapeutics, Inc. hold a median 12-month price target of $26 — +37.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$4.1B
Ticker Nerd rank
71 / 100
Median analyst target
$26
Analysts covering
14
Revenue$350K−48.3% y/y
Operating income−$90.8M
Net income−$83.7M
Free cash flow−$54.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.7%
1M
−5.6%
YTD
+123.0%
1Y
+358.0%
From 52W high
−9.1%
From 52W low
+372.9%
$4
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RLAY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Relay Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Value
84
Quality
74
Accruals
69
Growth
66
Volatility
48
Issuance
41
Revisions
39
Size
26

Momentum (98): The shares have been drifting up relative to others.

Revisions (39): Analysts have, on balance, been cutting their forecasts.

Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RLAY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RLAY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26RLAYHigh $32Median $26Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $20Median $26High $32

The green dot is the last close — the median target sits +37.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
20 Aug 2026HC Wainwright & Co.MaintainsBuy$28 → $29
14 Aug 2026JP MorganMaintainsOverweight$28 → $31
10 Aug 2026CitizensMaintainsMarket Outperform—
10 Aug 2026CitizensMaintainsMarket Outperform$21 → $26
7 Aug 2026BarclaysMaintainsOverweight—
7 Aug 2026BarclaysMaintainsOverweight$27 → $30
21 July 2026Goldman SachsMaintainsBuy$22 → $31
21 July 2026Goldman SachsMaintainsBuy—
16 July 2026Canaccord GenuityInitiatesBuy$29
16 July 2026Canaccord GenuityInitiatesBuy—
8 July 2026JP MorganInitiatesOverweight—
26 May 2026GuggenheimMaintainsBuy—
26 May 2026HC Wainwright & Co.MaintainsBuy—
20 May 2026BarclaysMaintainsOverweight—
20 May 2026CitizensMaintainsMarket Outperform—
19 May 2026Raymond JamesMaintainsStrong Buy—
29 Apr 2026HC Wainwright & Co.MaintainsBuy—
28 Apr 2026CitizensMaintainsMarket Outperform—
28 Apr 2026Goldman SachsMaintainsBuy—
28 Apr 2026OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RLAY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RLAY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Relay Therapeutics, Inc. returned +358.0% against +17.5% for the S&P 500, dividends included.

RLAY vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26RLAYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RLAY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
8
Fundamentals

Relay Therapeutics, Inc. (RLAY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.7×

Cheaper than 94% of US stocks

Price / sales
399.5×

Cheaper than 2% of US stocks

Price / book
4.6×

Cheaper than 22% of US stocks

EV / EBITDA
−10.6×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−48.3%

Higher than 6% of US stocks

Earnings growth (YoY)
−48.3%

Higher than 11% of US stocks

Gross margin
—
Operating margin
−25949.7%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.8%

Higher than 25% of US stocks

Return on assets
−22.9%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Relay Therapeutics, Inc. (RLAY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Relay Therapeutics, Inc. has a market value of $4.1B and an enterprise value of $3.3B.

  • Revenue in the twelve months to 30 June 2026: $10.3M. The latest quarter shrank 48.3% year on year.

  • Net income over the same four quarters: −$286.0M, a −2763.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.57.

  • Free cash flow in the twelve months to 30 June 2026: −$212.2M.

  • Shares outstanding: 218.5M.

  • Trailing P/E: −11.7×; forward P/E: −11.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Relay Therapeutics, Inc. employs 202 people — $51K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

RLAY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RLAYRelay Therapeutics, Inc.$4.1B
71
CELCCelcuity, Inc.$4.1B
27
MANEVeradermics, Inc.$4.1B
2
ELVNEnliven Therapeutics, Inc.$3.9B
68
TNGXTango Therapeutics, Inc.$3.9B
41
IOVAIovance Biotherapeutics, Inc.$3.8B
90
PBLSParabilis Medicines, Inc.$4.4B
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Relay Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RLAY news & analysis

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Seeking Alpha · 10 Sept 2026neutral

Relay Therapeutics presented prepared remarks at the Wells Fargo 21st Annual Healthcare Conference, with the remarks transcript published by Seeking Alpha. The presentation covered the company's prepared remarks at the investor conference.

Why it matters — A RLAY watcher would care because the conference presentation offers insight into how the company communicates its business and pipeline to the investment community.

Relay Therapeutics CFO Sells 17,717 Shares for $350,000

The Motley Fool · 2 Sept 2026neutral

Relay Therapeutics' CFO sold 17,717 shares in a transaction valued at approximately $350,000. The sale reduced the executive's direct equity position by 11%.

Why it matters — A watcher of Relay Therapeutics would care because this insider sale reveals a notable reduction in the CFO's direct equity stake in the company.

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

GlobeNewsWire · 1 Sept 2026neutral

Relay Therapeutics announced that its management will participate in two upcoming investor conference fireside chats in September. The company described itself as a clinical-stage precision medicine developer focused on cancer and genetic disease therapies.

Why it matters — This indicates management's ongoing engagement with the investment community during September, giving RLAY watchers visibility into the company's presence at investor events.

This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion

Investors Business Daily · 20 Aug 2026positive

Relay Therapeutics, whose stock has surged 1,027% off a low, is using artificial intelligence and machine learning to drive further momentum, according to Investor's Business Daily.

Why it matters — A RLAY watcher would care because the company's AI-driven drug-discovery platform is being highlighted as a key factor behind its recent stock surge.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Zacks Investment Research · 17 Aug 2026neutral

Zacks highlighted RLAY among four companies using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines. The article presents RLAY as one of several AI-powered drug discovery stocks to watch as AI reshapes pharma.

Why it matters — RLAY watchers would care because the company is being recognized for leveraging AI in its drug discovery approach while also advancing its own clinical pipeline.

FAQ

Frequently asked questions about RLAY stock

What is the RLAY stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Relay Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RLAY stock a buy right now?

Of the 14 analysts covering Relay Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relay Therapeutics, Inc. 71 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RLAY?

As at 12 Sept 2026, Relay Therapeutics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will RLAY stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +37.8% from the last close, and Ticker Nerd's factor model ranks Relay Therapeutics, Inc. 71 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RLAY stock forecast for 2030?

No analyst covering Relay Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.

How has RLAY stock performed over the past year?

Relay Therapeutics, Inc. returned +358.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Relay Therapeutics, Inc. do?

Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease.

What is the latest news on RLAY?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript". Relay Therapeutics presented prepared remarks at the Wells Fargo 21st Annual Healthcare Conference, with the remarks transcript published by Seeking Alpha. The presentation covered the company's prepared remarks at the investor conference.

Company

About Relay Therapeutics, Inc.

Relay Therapeutics Inc. is a clinical-stage precision medicines company focused on discovering and developing small-molecule therapies for oncology and genetic disease. The company uses its proprietary Dynamo platform to combine computational modeling, structural biology, medicinal chemistry, and experimental biology in order to address protein targets that have been difficult to drug with conventional methods. Its current pipeline centers on targeted cancer programs, including candidates for genetically defined tumors, as well as selected genetic disease applications. Relay Therapeutics Inc. operates in the biopharmaceutical sector with a strong emphasis on precision oncology, where it aims to design more selective therapies for molecularly characterized diseases. Based in Cambridge, Massachusetts, the company works at the intersection of drug discovery technology and clinical development, making it a notable participant in the small-molecule precision medicine market.

CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS · 202 employees · United States · https://www.relaytx.com